Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ISH0688
- Development stage
- Phase 1
- Lead developer
- SUNHO BioPharmaceutical
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
ISH0688 is a recombinant human IgG1 Fc-fibroblast growth factor 21 (FGF21) fusion protein developed by SUNHO BioPharmaceutical for the treatment of metabolic disorders, including hyperlipidemia and hypertriglyceridemia. FGF21 is a metabolic hormone that plays a crucial role in regulating glucose and lipid homeostasis, improving insulin sensitivity, and promoting energy expenditure. By fusing the FGF21 moiety with an IgG1 Fc fragment, ISH0688 is designed to have an extended half-life, allowing for a once-monthly (Q4W) subcutaneous dosing regimen. In clinical studies, it is being evaluated for its safety, tolerability, and ability to improve lipid profiles in patients with elevated triglycerides and cholesterol.
- Other names
- ISH0688 for injectionISH-0688 for injectionISH 0688 for injection
02
Targets
FGFR-KLB complex (Fibroblast growth factor receptor 1c / beta-Klotho complex)FGFR3 (Fibroblast growth factor receptor 3)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on ISH0688.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ISH0688.